Canavan disease

Lore & Background

Canavan disease was first described in 1931 by Myrtelle Canavan, who co-wrote a paper discussing the case of a child who had died at 16 months old and whose brain had a spongy white section. Canavan was the first to identify this degenerative disorder of the central nervous system, which was later named Canavan disease.

The disease is caused by a defective ASPA gene responsible for producing the enzyme aspartoacylase. Decreased aspartoacylase activity prevents normal breakdown of N-acetylaspartate, whose accumulation interferes with growth of the myelin sheath. The disorder is inherited in an autosomal recessive fashion; when both parents are carriers, the chance of having an affected child is 25%.

A lawsuit arose after the discovery of the gene. In 1987, a family donated tissue samples to researcher Reuben Matalon, who identified the gene in 1993 and developed a test. After Matalon relocated to Florida, Miami Children's Hospital patented the gene and claimed royalties, forcing the Canavan Foundation to withdraw free testing. A subsequent lawsuit was resolved with a sealed out-of-court settlement.

Reader's Guide

Canavan disease is significant as one of the most common degenerative cerebral diseases of infancy and a classic example of an autosomal recessive leukodystrophy. Its discovery by Myrtelle Canavan in 1931 established a distinct neurodegenerative disorder. The identification of the ASPA gene and the enzyme aspartoacylase deficiency clarified the pathophysiology, linking accumulation of N-acetylaspartate to myelin degeneration. The disease's prevalence among Ashkenazi Jewish populations (about 1 in 40 carriers) has made it a focus for genetic counseling and carrier screening. The controversy over gene patenting—where Miami Children's Hospital patented the Canavan gene and demanded royalties on testing—raised ethical and legal questions about ownership of genetic information and access to diagnostics. Experimental treatments, including lithium citrate, triacetin supplementation, and gene therapy using adeno-associated virus, have shown promise in animal models and early human trials, though no cure exists. The case illustrates the intersection of rare disease research, genetic testing, and intellectual property law.

Did You Know?

• Canavan disease was first described in 1931 by Myrtelle Canavan, who co-wrote a paper on a child who died at 16 months with a spongy white brain section.
• About 1 in 40 individuals of Eastern European (Ashkenazi) Jewish ancestry is a carrier of Canavan disease.
• A lawsuit over patenting of the Canavan gene by Miami Children's Hospital was resolved with a sealed out-of-court settlement.
• Experimental gene therapy using a modified adeno-associated virus has shown marked improvements, including myelin growth and decreased N-acetylaspartate levels.

The Clinical Picture and Disease Progression

Canavan disease is among the most prevalent degenerative conditions affecting the brain in infancy, and its most severe form announces itself within the first three to six months of life. From that point, the deterioration accelerates quickly. Infants lose motor milestones they had already achieved, develop feeding problems, and show a striking shift in muscle tone—beginning with a floppy, hypotonic state that can later harden into spasticity. Poor head control and an abnormally enlarged head (megalocephaly) are hallmark features. In more advanced cases, paralysis, blindness, and seizures join the clinical picture. The underlying damage is to the myelin phospholipid layer that insulates neuronal axons, a process classified under the broader family of leukodystrophies. A rarer, milder variant exists, presenting later with vague speech and motor delays that are often missed entirely; this form does not appear to shorten life. Because inheritance is autosomal recessive and the responsible gene sits on chromosome 17, two carrier parents face a one-in-four chance of passing the condition to a child, making genetic counseling a critical step for at-risk families.

The Biochemical Defect and How It Is Detected

At the molecular level, Canavan disease stems from a malfunctioning ASPA gene that fails to produce adequate aspartoacylase, the enzyme normally responsible for breaking down N-acetylaspartate. When that breakdown stalls, N-acetylaspartate piles up inside brain tissue, and its toxic accumulation disrupts the growth of the myelin sheath—the fatty insulating wrap around nerve fibers that enables fast, efficient transmission of electrical impulses. Without healthy myelin, neural signaling deteriorates throughout the central nervous system. Detecting the condition depends on the severity of the presentation. In the classic infantile form, a straightforward urine test reveals markedly elevated levels of N-acetylaspartic acid, providing a clear diagnostic marker. In the milder juvenile variant, however, NAA levels may be only modestly raised, making biochemical screening unreliable. In those cases, clinicians turn to molecular genetic testing of the ASPA gene itself to confirm the diagnosis. Because the disorder follows an autosomal recessive pattern, couples in which both partners carry a defective copy each face a twenty-five percent risk of having an affected child, underscoring the importance of pre-conception or antenatal genetic counseling.

Treatment Landscape and Experimental Hope

No cure currently exists for Canavan disease, and there is no single standardized protocol. Management is therefore symptomatic and supportive: physical therapy aims to preserve or improve motor function, structured educational programs target communication development, antiepileptic medications control seizures, and a gastrostomy tube can be placed to guarantee adequate nutrition and hydration when swallowing becomes unsafe. Beyond these measures, several experimental approaches have generated cautious optimism. Lithium citrate, tested in a rat genetic model, significantly lowered N-acetylaspartate levels; when tried in a human subject, the individual's condition appeared to reverse during a two-week wash-out period after the drug was withdrawn, and brain-region measurements showed NAA values shifting toward normal myelination patterns, prompting calls for a larger controlled trial. Gene therapy offers another frontier: a 2002 study introduced a healthy copy of the ASPA gene to compensate for the defective one, and a 2012 publication of human trial results reported that the approach improved the patient's quality of life without long-term adverse effects over a five-year follow-up. Triacetin supplementation, which the body can cleave into acetate that crosses into the brain more readily than its charged counterpart, has also shown promise in animal models.

Origins, the Gene Patent Dispute, and Community Impact

The condition bears the name of Myrtelle Canavan, who in 1931 co-authored a paper describing the brain of a child who had died at sixteen months and displayed a distinctive spongy white region. She was the first to recognize this as a distinct degenerative disorder of the central nervous system, and the eponym stuck. Decades later, the disease's genetic basis became the center of an ethical storm. In 1987, the Greenberg family, who had two children affected by Canavan disease, donated tissue samples to Reuben Matalon at the University of Chicago. By 1993 he had identified the responsible gene and built a diagnostic test that enabled antenatal counseling for at-risk couples; the Canavan Foundation initially distributed the test free of charge. In 1997, after Matalon moved to Miami Children's Hospital, his new employer patented the gene and began collecting royalties, forcing the Foundation to pull its free-testing program. The Foundation sued; the case ended in a sealed out-of-court settlement but remains a frequently cited example in debates over whether genes should be patentable. The condition is most prevalent among people of Eastern European Jewish descent, where roughly one in forty individuals carries a defective copy.

Gallery